Fig. 8: Adoptive therapy with WT macrophages rescues the function of T cells in LXN-deficient mice.

A Schematic representation of the mouse model of cell adoptive therapy for in the subcutaneous tumor models. Macrophages isolated from bone marrow of WT and LXN KO mice were labeled with CFSE. MC38 cells were engrafted into the subcutaneously of LXN KO mice. The CFSE-labeled WT or LXN KO-macrophages were injected twice through the tail vein at the indicated time points. B Animal imaging shows the enrichment of CFSE-labeled macrophages at the tumor site (i) and other organs (ii), as shown by the white arrow. C Representative the tumor growth curves. n = 9, *P < 0.05, **P < 0.01, n.s. no significance. D Imaging of tumor tissues of tumor-bearing recipient LXN KO mice that were treated with CFSE-labeled WT or LXN KO-Macrophages, and the tumor weight at the end point was shown. n = 9. E Representative FACS plots and frequencies of F4/80⁺CD11b⁺PD-L2⁺ macrophages in subcutaneous tumors treated with WT or LXN KO-Macrophages. n = 6, ***P < 0.001, n.s. no significance. M Representative FACS plots and frequencies of CD3⁺CD4⁺ and CD3⁺CD8⁺ T cells in subcutaneous tumors treated with WT or LXN KO-Macrophages. n = 6, *P < 0.05, **P < 0.01, ***P < 0.001.